Nat. Commun.
8, 167.
Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor.
2017
Roymans, D., Alnajjar, S.S., Battles, M.B., Sitthicharoenchai, P., Furmanova-Hollenstein, P., Rigaux, P., Berg, J.V.D., Kwanten, L., Ginderen, M.V., Verheyen, N., Vranckx, L., Jaensch, S., Arnoult, E., Voorzaat, R., Gallup, J.M., Larios-Mora, A., Crabbe, M., Huntjens, D., Raboisson, P., Langedijk, J.P., Ackermann, M.R., McLellan, J.S., Vendeville, S. and Koul, A.
Notes: A cocrystal structure of novel therapeutic, JNJ-53718678, for respiratory syncytial virus is presented bound to the respiratory syncytial virus fusion (F) protein (RSVF). Treatment of infected lambs and rodents with JNJ-53718678 lead to efficient inhibition of infection. Additionally, the antiviral activity of JNJ-53718678 against an alternative virus, dengue virus type 2 (DENV-2), was tested using the EnduRen™ Live Cell Substrate. (5116)
Expand Full Notes »